Cubist Systematic Strategies LLC Grows Stock Position in Paysign, Inc. (NASDAQ:PAYS)

Cubist Systematic Strategies LLC boosted its stake in shares of Paysign, Inc. (NASDAQ:PAYS) by 27.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 39,579 shares of the company’s stock after buying an additional 8,444 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.07% of Paysign worth $120,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. PDT Partners LLC bought a new position in shares of Paysign during the 4th quarter worth $39,000. Wells Fargo & Company MN grew its position in shares of Paysign by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 15,385 shares of the company’s stock worth $46,000 after buying an additional 5,243 shares in the last quarter. SG Americas Securities LLC boosted its position in Paysign by 33.5% during the fourth quarter. SG Americas Securities LLC now owns 15,508 shares of the company’s stock valued at $47,000 after purchasing an additional 3,895 shares in the last quarter. Virtu Financial LLC bought a new stake in Paysign during the fourth quarter valued at about $78,000. Finally, Bard Associates Inc. boosted its position in Paysign by 19.7% during the fourth quarter. Bard Associates Inc. now owns 33,450 shares of the company’s stock valued at $101,000 after purchasing an additional 5,497 shares in the last quarter. Hedge funds and other institutional investors own 25.89% of the company’s stock.

Paysign Stock Down 6.0%

NASDAQ:PAYS opened at $3.61 on Monday. Paysign, Inc. has a 52 week low of $1.80 and a 52 week high of $5.59. The company has a market capitalization of $195.73 million, a P/E ratio of 24.07 and a beta of 0.23. The stock’s fifty day moving average is $2.36 and its two-hundred day moving average is $2.81.

Paysign (NASDAQ:PAYS) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.01. The company had revenue of $18.60 million for the quarter, compared to the consensus estimate of $17.49 million. Paysign had a return on equity of 30.64% and a net margin of 14.28%. Sell-side analysts anticipate that Paysign, Inc. will post 0.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PAYS shares. Lake Street Capital raised their price objective on Paysign from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, May 9th. LADENBURG THALM/SH SH raised their price target on Paysign from $7.25 to $8.25 and gave the stock a “buy” rating in a report on Friday, May 9th. DA Davidson raised their price target on Paysign from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday, May 14th. Finally, Barrington Research reissued an “outperform” rating and issued a $7.00 price target on shares of Paysign in a report on Wednesday, March 26th.

Insider Activity at Paysign

In other Paysign news, CEO Mark Newcomer sold 100,000 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $2.73, for a total transaction of $273,000.00. Following the transaction, the chief executive officer now owns 8,936,886 shares in the company, valued at $24,397,698.78. The trade was a 1.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.40% of the stock is owned by insiders.

About Paysign

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.